Fed­er­al ap­peals court heav­i­ly ques­tions FDA, Dan­co lawyers in abor­tion drug case

The fate of the abor­tion drug mifepri­s­tone is still up in the air in the US af­ter three fed­er­al ap­peals court judges heav­i­ly ques­tioned the gov­ern­ment and Dan­co Lab­o­ra­to­ries over whether the FDA fol­lowed the prop­er process when it loos­ened ac­cess to the drug.

Mifepri­s­tone was first ap­proved by the FDA in 2000, and the reg­u­la­tor made a num­ber of changes in 2016 that broad­ened ac­cess to the prog­es­terone block­er, in­clud­ing al­low­ing it to be shipped in the mail and pre­scribed by a wider range of health­care pro­fes­sion­als, not just physi­cians.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER